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Abstract: Our current understanding of cancer-stem cells (CSCs) is that they are slow growing, generally mesenchymal-
like cells capable of generating tumors. Convincing evidence for the existence of such cells comes from recent lineage 
tracing experiments. CSCs have been reported as being resistant to conventional drug treatment and have been considered 
as being responsible for failure of chemotherapy. Recently, several databases aiming the genetic characterization of a 
large number of cancer cell lines have been made publicly available. In addition to gene expression data, these databases 
contain cytotoxicity information for all cell lines for a number of drugs as well. It is possible to classify known cell lines 
derived from a given tumor, based on how similar they are to CSCs, or in other words, to define their stem-ness, using 
gene-lists that define such cells. Using two such, independently generated, gene lists we found that breast cancer cell lines 
could be categorized into two distinct groups which we designate CSC-like and non-CSC-like. We then identified drugs to 
which the two groups were most sensitive to. We also generated sensitivity profiles for all drugs, within one such 
database, to identify chemotherapeutics with preferential action on breast cancer. We believe this is a straight-forward 
approach for swiftly identifying drugs that would selectively target a subpopulation of cells for any given tumor type.  
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INTRODUCTION 
 Despite decades of work, cancer remains mostly an 
incurable disease. One reason for drug resistance in cancer 
has been proposed to stem from the fact that tumors contain 
cancer stem cells (CSCs) that can resist therapy. Recently, 
several papers have clearly documented the presence of 
CSCs using lineage tracing [1]. However, markers by which 
such cells can be reproducibly identified in tumors has been 
difficult due to the fact that tumors show vast heterogeneity 
[2]. Nevertheless, many ongoing studies aim to identify agents 
that can target cancer stem cells, as it is agreed that such 
cells are difficult to kill using conventional drugs. A recent 
COST action (CM1106) made its priority to characterize 
such drugs and many other studies have been or are being  
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conducted with the same purpose. The logic behind these is 
that cells defined by either a marker or a behavior should be 
tested for drug sensitivity. However, as we show in this study, 
in cases where a gene expression profile for a CSC-like cell 
is available, it is possible to use this signature to classify 
commonly used cancer cell lines into CSC-like and non-
CSC-like populations. This information can then be used to 
identify drugs that affect either population better than the 
other, and thus predict drugs with preferential action on both 
CSC-like and non-CSC-like cells. We believe annotating 
drugs for both populations is critical in that there is building 
evidence that either group can cause cancer mortality,  
due to the phenotypic plasticity allowing transition between 
phenotypes. An extremely useful source for this purpose is 
the drug cytotoxicity data provided within the Cancer Cell 
Line Encyclopedia (CCLE) project [3]. We here show that it 
is possible to identify drugs that can possibly be selected for 
validation studies, even when their effects on purified CSCs 
are not yet available.  
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MATERIALS AND METHODS 
In Silico Classification of Breast Cancer Cell Lines and 
Identification of Drugs with Differential Effects 
 The GSE36133 dataset containing expression data from 
all cell lines with drug screening data in the CCLE project 
was RMA normalized using GeneSpring v.12.5. Breast 
cancer cell lines were hierarchically clustered based on the 
probeset lists reported by Gupta et al. [4] or Kao et al. [5]; 
with Euclidian distance measures for both genes and arrays, 
and complete linkage, using Cluster 3.0 software. Drug toxicity 
data was obtained from the CCLE project (http://www. 
broadinstitute.org/ccle) [3]. Groups identified as CSC-like 
and non-CSC-like were compared using t-test (2-sided, equal 
variance) for all parameters (activity area, Amax, IC50, and 
EC50). p≤0.05 was considered statistically significant. 
ANNOTATING GLOBAL EFFECTS OF DRUGS ON 
CANCER CELL LINES 
 Drug toxicity (activity area) data was obtained for all 
drugs contained within the CCLE project database [3], and 
was plotted for each cell line type following mean-sorting, 
using the “boxplot” function of the graphics package of R 
[6]. Cell line annotations are those provided by CCLE, 
except for the two breast cancer cell types which were 
identified in this study.  
RESULTS 
In Silico Classification of Breast Cancer Cell Lines into 
CSC-Like and Non-CSC-Like Populations 
 Several recent studies have generated gene lists that 
define CSC-like populations. One such list generated by 
Gupta et al, consists of genes differentially expressed in cells 
that resist paclitaxel but are sensitive to salinomycin, drugs 
known to effect non-CSCs or CSCs, respectively. The list 
was validated based on its ability to correctly identify breast 
CSCs as defined by other methods [4]. We asked if this 
signature could be used to differentiate commonly used 
breast cancer cell lines into distinct populations. Indeed, 
hierarchical clustering of the 27 breast cancer cell lines with 
screening data in the CCLE project revealed two distinct 
clusters, one that contained 6 cell lines which up-regulated 
most CSC-related genes and down-regulated all genes 
associated with non-CSCs, clearly categorizing them as 
CSC-like. The second cluster behaved in exactly the opposite 
manner, indicating that they were, or at least contained, 
primarily non-CSC or epithelial cells (Fig. 1). In another 
study aiming to classify breast cancer cell lines into subgrups, 
Kao et al. revealed the presence of 3 distinct subtypes which 
they coined basal-A, basal-B and luminal [5]. When we used 
this gene list to cluster all CCLE breast cancer cell lines, we 
observed that all CSC-like cells as defined by Gupta et al.’s 
 
Fig. (1). Hierarchical clustering of the 27 breast cancer cell lines used in the CCLE project with a breast CSC signature (ref. 4). The 
list used for clustering contains 14 genes that are down-regulated (D), and 25 that are upregulated (U) in salinomycin-sensitive cells (CSCs). 
Clustering of the CCLE cell lines reveals two distinct groups, one which shows the same expression pattern as CSCs, which we therefore, 
denote “CSC-like”(A). The second cluster, behaves in the opposite fashion, and are therefore, coined “non-CSC-like” or epithelial cells (B). 
Colors are standardized to represent maximum and minimum expression for each gene. Red: up-, green: down-regulation. 
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list corresponded to basal-B cells, while non-CSC-like cells 
were basal-A or luminal type cell lines (Supplementary Fig. 1). 
In our analysis, basal-B cells formed an independent cluster, 
while basal-A and luminal cells co-clustered. Thus, two 
independent gene lists classified existing breast cancer cell 
lines into the same two major groups.  
IDENTIFYING DRUGS TARGETING CSC-LIKE 
BREAST CANCER CELL LINES 
 The CCLE database contains cytotoxicity data reported 
as 4 different parameters (IC50, EC50, Amax and activity 
area) for 24 drugs. Using this data, we determined drugs 
which showed statistically different effects on the CSC-like 
 
Fig. (2). Drugs with differential effects on CSC-like and non-CSC-like cells. Inhibitory effects that are significantly different among 
CSC-like (C) and non-CSC-like (E) cell lines are shown. Drugs: Lapatinib (a-c), TKI258 (d-f), 17AAG (g), L685458 (h), and Panobinostat 
(i). The measure of cytotoxicity for which significance was observed is indicated on the y-axis. Increased activity area, or decreased Amax, 
IC50 or EC50 values indicate increased drug sensitivity. Box includes values between the 25th and 75th percentiles, with the median 
indicated. Whiskers are from the minimum to the maximum value. P values obtained by the two-tailed t-test are: a: 0.03, b: 0.02, c: 0.01, d: 
0.01, e: 0.01, f: 0.02, g: 0.04, h: 0.01, i: 0.05. 
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and non-CSC-like cell lines. We thus identified TKI258 
(dovitinib, a FGFR, VEGFR and PDGFR inhibitor) and L-
685458 (a γ -secretase inhibitor) as agents that were 
preferentially active on CSC-like cells. TKI258 showed 
significantly better toxicity on the CSC-like cells when 
analyzed using 3 of the 4 parameters of cell viability (Fig. 2). 
Non-CSC cells were relatively sensitive to Lapatinib (a dual 
HER2/neu and EFGR inhibitor), 17-AAG (a HSP90 
inhibitor), and Panobinostat (histone deacetylase inhibitor). 
Significant sensitivity to Lapatinib was evident from analysis 
performed with 3 out of 4 measures of cytotoxicity (Fig. 2). 
GLOBAL DRUG EFFECTS ON CANCER CELL 
LINES BASED ON TISSUE OF ORIGIN 
 Comparing two groups of cells, albeit useful, has a caveat 
in that a drug with excellent toxicity for both groups will not 
be identified if it affects both groups similarly, or 
alternatively if the drug’s active concentration range is 
narrow. To overcome this caveat we wanted to view the 
“overall” effect of all CCLE drugs on all cancer cell lines 
including the two breast cancer cell line groups we 
identified. We chose “activity area” as the reference measure 
as it generates a value for each cell/treatment condition as 
opposed to IC50 or EC50. When tumor cell lines, grouped 
by tissue of origin, were sorted based on the mean value for 
activity area from lowest (most active) to the highest (least 
active) for TKI258, we observed that the two breast cancer 
subpopulations were indeed quite distant from each other 
(Fig. 3). However, the fact that the non-CSC-like breast 
cancer cell lines were among the most resistant to this drug, 
obviously contributed to the significant difference observed 
between the two cell groups. Thus, it needs to be determined 
whether the doses of this drug at which CSC-like cells are 
affected can be tolerated in vivo. If most CSC-like cells are 
within this range, then the drug would be a suitable agent for 
treating CSC-like breast cancer cells. Similar analyses 
 
Fig. (3). TKI258 sensitivity of tumor cell lines. TKI258 activity on cell lines (activity area) grouped by tissue of origin is shown. Box 
represents 25th to 75th percentile, and whiskers the 2 standard deviations above and below the mean value of the activity area values obtained 
for each cell line type. Outliers are represented by circles. Line indicates the median. Cell lines are mean-sorted from the most sensitive (left) 
to the least. CSC-like (green) and non-CSC-like (red) breast cancer cell lines are indicated. 
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revealed that the B-Raf and VEGFR2 inhibitor Raf265, 
although not significant by t-test analysis, was in fact a better 
differentiator of the two breast cancer cell line populations 
based on how far apart the two populations were in this 
graphic (Supplementary Fig. 2). Again, the value of this 
observation strongly depends on the effective dose range of 
the drug in vivo. The non-CSC-like breast cancer cells, on 
the other hand, were found to be the most sensitive cells, 
compared to all other cancers when evaluated for lapatinib 
toxicity. In contrast, CSC-like breast cancer cells were very 
resistant to lapatinib (Fig. 4). This is an interesting finding as 
lapatinib has been recently approved for hormone-positive 
and HER2 positive breast cancer treatment. Even if most 
non-CSC-like breast cancer cells are sensitive to this agent, 
our data suggests that lapatinib treatment alone will likely 
not affect CSC-like breast cancer cells. In contrast, the IAP 
(inhibitor of apoptosis) inhibitor LBW242 was the drug to 
which the CSC-like breast cancer cells were most sensitive, 
when compared to all other drugs (Supplementary Fig. 3). 
The drug is only moderately toxic for non-CSC-like breast 
cancer. Therefore, if tumors are found to contain a mixture 
of CSC-like and non-CSC-like populations, this analysis 
suggests that lapatinib/LBW242 combination therapy could 
be worth further validation.  
DISCUSSION 
 We herein describe two straight-forward approaches by 
which large-scale gene expression and drug sensitivity data 
can be utilized to identify suitable chemotherapeutics for a 
given cell type. Our first approach is based on defining 
subsets of cell lines based on published gene lists. It is 
interesting to observe how two such independent lists 
generate the same clusters for breast cancer cell lines. Gene 
lists have been used to reproducibly cluster breast cancer into 
“intrinsic subtypes” that consist primarily of luminal and 
basal types [7, 8]. It is, therefore, not surprising that 
 
Fig. (4). Lapatinib sensitivity of tumor cell lines. Lapatinib activity on cell lines (activity area) grouped by tissue of origin is shown. Box 
represents 25th to 75th percentile, and whiskers the 2 standard deviations above and below the mean value of the activity area values obtained 
for each cell line type. Outliers are represented by circles. Line indicates the median. Cell lines are mean-sorted from the most sensitive (left) 
to the least. CSC-like (green) and non-CSC-like (red) breast cancer cell lines are indicated. 
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signatures consisting of the most differentially expressed 
genes among cell groups overlap with the intrinsic subtypes. 
On the other hand, that such a classification reflects a stem-
cell character is in our opinion very valuable. This not only 
implies that such cell lines can represent CSCs, but it also 
suggests that larger numbers of cells within a tumor might 
take upon themselves a stem-like character. In fact, the 
mechanism behind epithelial to mesencymal transition (EMT) 
or its reverse (MET), is exactly this [9]. Mesenchymal  
cells are slow growing, less differentiated, invasive and 
tumorigenic cells, resembling CSCs in many ways. In this 
line, for melanoma, colorectal cancer and others, EMT or a 
similar profile of “switchable” phenotypes has been 
associated with the tumorigenesis process or the variation of 
cells within the tumor. Therefore, even if cell line subtypes 
do not consist of CSCs exclusively, they still can represent 
behavior of such cells. Nevertheless, analyses described 
within this study do not eliminate the need for validation 
studies where CSC-like cells would be tested for qualities of 
colony formation, proliferation, invasion and such to 
demonstrate a functional similarity to CSCs. As the drug 
effects predicted in this study are very likely to be 
reproduced if the same cells are tested in vitro, it would be 
important to perform clustering and cell toxicity experiments 
in cells that are not included in the CCLE cell line cohort. In 
this study, paclitaxel activity on CSC-like and non-CSC-like 
cells was not found to differ significantly. As Gupta et al. 
showed differential toxicity of this drug against the two 
populations, the two cell populations identified here in in 
Gupta et al.’s study are not identical [4]. However, as 
different subtypes of breast cancer (represented by the cell 
subtypes identified in this study) are known to benefit from 
different chemotherapeutics, it could be argued that even if 
cell line sub-populations are not CSCs, they do represent a 
distinct phenotype that resembles CSCs in certain aspects. 
The validity of the approach described in this study will be 
strengthened if drugs that are found to affect CSC-like cells 
are also able to kill phenotypically similar populations of 
CSCs. 
 We believe, a global view of drug sensitivity, showing 
sensitivity profiles of all tumor cells for a given drug, is 
helpful in determining chemotherapeutics better suited for 
clinical use for a given tumor type. A most striking finding is 
that among all cell lines, non-CSC-like breast cancer cells 
are most sensitive to lapatinib, a drug currently approved for 
breast cancer treatment. Equally revealing, is the finding that 
CSC-like cells are relatively resistant to the same drug, when 
they are sensitive to agents like LBW242 or Raf265. Thus, 
our analysis reveals the presence of two distinct breast 
cancer cell types for which different treatment regimens 
might be appropriate and those drugs that are candidates for 
combination therapy. All drugs within the CCLE database are 
FDA-approved, and have a limited effective concentration 
range. Generating the in vitro counterpart to the maximum 
tolerable in vivo dose for cell lines, combined with this 
global analysis, would be very helpful in identifying tumor 
types for which a given drug is suitable in vivo.  
CONCLUSION 
 We show that the classification of breast cancer cell lines 
into phenotypically distinct groups facilitates the 
identification of chemotherapeutics that might individually 
target CSC-like as well as non-CSC-like cells. The overall 
drug sensitivity profile of cell lines, on the other hand, 
reveals that drugs like Raf265 or LBW242 might affect 
CSC-like breast cancer cell lines at concentrations that are 
possibly well tolerated.  
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Supplementary Fig. (1). Hierarchical clustering analysis of CCLE breast cancer cell lines with Kao et al.’s gene list (ref. 5). Cluster 
analysis of all breast cancer cell lines, including those that were previously analyzed by Kao et al. (ref. 5), reveal three groups: Luminal 
(blue), Basal A (red) and Basal B (yellow). The heatmap and details of the cluster are shown. The 6 CSC-like cell lines are all of the “Basal 
B” type. The gene list used for clustering included  12628 probesets corresponding to 5771 of the 8750 genes used for the original analysis, as 
only these genes had corresponding annotations for the HGU 133 Plus 2.0 platform. 
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Supplementary Fig. (2). RAF265 sensitivity of tumor cell lines. RAF265 activity on cell lines (activity area) grouped by tissue of origin is 
shown. Box represents 25th to 75th percentile, and whiskers the 2 standard deviations above and below the mean value of the activity area 
values obtained for each cell line type. Outliers are represented by circles. Line indicates the median. Cell lines are mean-sorted from the most 
sensitive (left) to the least. CSC-like (green) and non-CSC-like (red) breast cancer cell lines are indicated.  
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Supplementary Fig. (3). LBW242 sensitivity of tumor cell lines. LBW242 activity on cell lines (activity area) grouped by tissue of origin is 
shown. Box represents 25th to 75th percentile, and whiskers the 2 standard deviations above and below the mean value of the activity area 
values obtained for each cell line type. Outliers are represented by circles. Line indicates the median. Cell lines are mean-sorted from the most 
sensitive (left) to the least. CSC-like (green) and non-CSC-like (red) breast cancer cell lines are indicated.  
 
 
